Clinical Trials Browser

Phase 2 × HER2-negative Breast Cancer Brain Metastases × Clear all

NCT06418594 2024-12-10

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Phase 2 Recruiting

HER2-negative Breast Cancer Brain Metastases